1. Repositório Aberto da Universidade do Porto
  2. ISPUP - Instituto de Saúde Pública
  3. ISPUP - Outra Publicação em Revista Científica Internacional
Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/159938
Full metadata record
DC FieldValueLanguage
dc.creatorYoo, SGK-
dc.creatorChung, GS-
dc.creatorBahendeka, SK-
dc.creatorSibai, AM-
dc.creatorDamasceno, A-
dc.creatorFarzadfar, F-
dc.creatorRohloff, P-
dc.creatorHouehanou, C-
dc.creatorNorov, B-
dc.creatorKarki, KB-
dc.creatorAzangoukhyavy, M-
dc.creatorMarcus, ME-
dc.creatorAryal, KK-
dc.creatorBrant, LCC-
dc.creatorTheilmann, M-
dc.creatorCífková, R-
dc.creatorLunet, N-
dc.creatorGurung, MS-
dc.creatorMwangi, JK-
dc.creatorMartins, J-
dc.creatorHaghshenas, R-
dc.creatorSturua, L-
dc.creatorVollmer, S-
dc.creatorBärnighausen, T-
dc.creatorAtun, R-
dc.creatorSussman, JB-
dc.creatorSingh, K-
dc.creatorMoghaddam, SS-
dc.creatorGuwatudde, D-
dc.creatorGeldsetzer, P-
dc.creatorManne-Goehler, J-
dc.creatorHuffman, MD-
dc.creatorDavies, JI-
dc.creatorFlood, D-
dc.date.accessioned2024-07-25T14:37:43Z-
dc.date.available2024-07-25T14:37:43Z-
dc.date.issued2024-
dc.identifier.issn2211-8160-
dc.identifier.issn2211-8179-
dc.identifier.urihttps://hdl.handle.net/10216/159938-
dc.description.abstractThe role of aspirin in the primary prevention of atherosclerotic cardiovascular disease (CVD) is not clear, with recent clinical trials evaluating aspirin for primary prevention demonstrating both modest benefits and risks associated with its use [1]. Aspirin is not routinely recommended for primary prevention of CVD. Understanding patterns of aspirin use can inform strategies to promote guideline-concordant therapy, including de-implementation strategies to reduce unnecessary aspirin use. This study seeks to provide an updated estimate of worldwide aspirin use for primary prevention of CVD. © 2024 The Author(s).pt_PT
dc.description.sponsorshipPG is a Chan Zuckerberg Biohub – San Francisco investigator. LB was supported in part by CNPq 307329/2022-4. DF was supported by the NHLBI (award number K23HL161271), the Michigan Center for Diabetes Translational Research (award number P30DK092926), the University of Michigan Claude D. Pepper Older Americans Independence Center (award number 5P30 AG024824), and the University of Michigan Caswell Diabetes Institute Clinical Translational Research Scholars Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.pt_PT
dc.language.isoengpt_PT
dc.publisherUbiquity Presspt_PT
dc.relation.ispartofGlob Heart. 2024 May 3;19(1):44. doi: 10.5334/gh.1323. eCollection 2024.-
dc.rightsopenAccesspt_PT
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.titleGlobal Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Datapt_PT
dc.typeOutra Publicação em Revista Científica Internacionalpt_PT
dc.contributor.uportoInstituto de Saúde Públicapt_PT
dc.identifier.doi10.5334/gh.1323-
dc.relation.publisherversionhttps://globalheartjournal.com/articles/10.5334/gh.1323-
Appears in Collections:ISPUP - Outra Publicação em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
yoo24.pdf1.68 MBAdobe PDFThumbnail
View/Open
Show simple item record Recommend this item Display Statistics


This item is licensed under a Creative Commons License Creative Commons